Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Avidity Biosciences, Inc. (RNA) EBT Margin (2019 - 2025)

Avidity Biosciences' EBT Margin history spans 7 years, with the latest figure at 27514.42% for Q4 2025.

  • For Q4 2025, EBT Margin fell 2406814.0% year-over-year to 27514.42%; the TTM value through Dec 2025 reached 3640.03%, down 68459.0%, while the annual FY2025 figure was 3640.03%, 68459.0% down from the prior year.
  • EBT Margin reached 27514.42% in Q4 2025 per RNA's latest filing, down from 1395.29% in the prior quarter.
  • In the past five years, EBT Margin ranged from a high of 881.69% in Q1 2021 to a low of 27514.42% in Q4 2025.
  • Average EBT Margin over 5 years is 3722.96%, with a median of 2050.92% recorded in 2021.
  • The largest YoY upside for EBT Margin was 203648bps in 2025 against a maximum downside of -2406814bps in 2025.
  • A 5-year view of EBT Margin shows it stood at 2078.4% in 2021, then grew by 12bps to 1822.07% in 2022, then plummeted by -51bps to 2751.39% in 2023, then fell by -25bps to 3446.28% in 2024, then tumbled by -698bps to 27514.42% in 2025.
  • Per Business Quant, the three most recent readings for RNA's EBT Margin are 27514.42% (Q4 2025), 1395.29% (Q3 2025), and 4072.37% (Q2 2025).